Outcome after chimeric antigen receptor ( CAR ) T‐cell therapy failure in large B‐cell lymphomas
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19057 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Anna Dodero und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Enhancement and strengthening of biomedical research in the NHS.
Abstract (Originalsprache)
This study retrospectively evaluated the outcome of salvage therapy in 51 patients who failed axicabtagene ciloleucel or tisagenlecleucel for relapsed/refractory large B‐cell lymphomas. Of these patients, 22 (43%) were enrolled in clinical trials (glofitamab or loncastuximab tesirine + ibrutinib), whereas 29 received standard therapies (lenalidomide [Len], checkpoint inhibitors [CPIs], ibrutinib [I], chemoimmunotherapy and radiotherapy) or supportive care. Overall, 26 of 39 (67%) treated patients received a treatment based on immunotherapy (glofitamab, CPI, Len) that was mainly represented by bispecific antibody ( n = 18). In this subgroup, plasma samples were collected and analysed for circulating tumour DNA (ctDNA) using cancer‐personalized profiling by deep sequencing (CAPP‐seq). The study found that patients with high ctDNA had poor outcomes. At a median follow‐up of 11.7 months, the estimated 12‐month overall survival (OS) was 35%. Factors adversely affecting the prognosis in the multivariable model were the absence of response to CAR T‐cell therapy (HR: 3.08; p = 0.0109) and a diagnosis other than PMBCL and t‐FL (HR: 4.54; p = 0.0069). The outcome of patients failing CAR T cells is poor and requires further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Department of Hematology, IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy.
- Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- University of Milano, Milan, Italy.
- Department of Biomedical Sciences, Humanitas University, Rozzano-Milan, Italy.
- Department of Hematology, Istituto Europeo di Oncologia, Milan, Italy.
ORCID-Profile: Anna Dodero, Annalisa Chiappella
Förderung
- Enhancement and strengthening of biomedical research in the NHS
Zitieren
APA
Dodero, A., Bramanti, S., Di Trani, M., Pennisi, M., Ljevar, S., Chiappella, A., Massimo, M., Guidetti, A., Corrado, F., Nierychlewska, P. M., Di Rocco, A., Lorenzini, D., Daoud, R., De Philippis, C., Santoro, A., Carlo-Stella, C., & Corradini, P. (2024). Outcome after chimeric antigen receptor ( CAR ) T‐cell therapy failure in large B‐cell lymphomas. British Journal of Haematology. https://doi.org/10.1111/bjh.19057
Vancouver
Dodero A, Bramanti S, Di Trani M, Pennisi M, Ljevar S, Chiappella A, et al. Outcome after chimeric antigen receptor ( CAR ) T‐cell therapy failure in large B‐cell lymphomas. British Journal of Haematology. 2024. doi:10.1111/bjh.19057
BibTeX
@article{Dodero2024,
author = {Dodero, Anna and Bramanti, Stefania and Di Trani, Martina and Pennisi, Martina and Ljevar, Silva and Chiappella, Annalisa and Massimo, Magagnoli and Guidetti, Anna and Corrado, Francesco and Nierychlewska, Paulina Maria and Di Rocco, Alice and Lorenzini, Daniele and Daoud, Rahal and De Philippis, Chiara and Santoro, Armando and Carlo-Stella, Carmelo and Corradini, Paolo},
title = {Outcome after chimeric antigen receptor ( CAR ) T‐cell therapy failure in large B‐cell lymphomas},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19057}
}
EUVIMED